About US
Contact us
-
AstraZeneca shuffles leadership ahead of megadeal close, tapping an Alexion CEO and bringing up a new CFOWith AstraZeneca's Alexion buyout due to close later this year, the British Big Pharma is summoningthe rare disease specialist'schief financial officer toits C-suite andtapping a new CEO for its priz2021/6/1
-
ASCO: Novartis' radiotherapy ambition takes a small hit as Lutathera relegated to 'clinically relevant' survival edgeRadiopharmaceuticals, along with cell and gene therapy, is one of the advanced drug platforms Novartis has pegged for long-term growth. But that ambition has hit a small setback. Lutathera, the fi2021/6/1
-
Biogen's $1B Swiss plant scores regulatory nod as drugmaker awaits pivotal FDA decision on aducanumabDespite a flurry of uncertainty surrounding Biogen’s Alzheimer's hopeful aducanumab, the company has forged ahead with its launch preparationsahead of a pending FDA decision. Now, itsSwiss manufactur2021/5/27
-
Apellis' PNH victory lap: Newly FDA-approved Empaveli helped patients without prior Soliris treatmentApellis Pharmaceuticals is taking a victory lap. Less than two weeks after the FDA approved Apellis’ C3 inhibitor pegcetacoplan, marketed as Empaveli, for patients with a rare blood disorder kn2021/5/27
-
With plant-based manufacturing platform, Medicago takes COVID-19 vaccine production into the greenhouseDuring the span of the COVID-19pandemic, mRNA vaccines have gone from being promising technology in the lab to blockbuster products in the real world.In the pandemic's second year,Medicago is hoping2021/5/24
-
Vectura, after reinventing itself as a CDMO, accepts $1.4B buyout offer from CarlyleA few short years after rebranding itself as a CDMO, inhalation specialist Vectura's pivot has paid off big time—courtesy ofprominent healthcare investment firm The Carlyle Group. Vectura has a2021/5/24
-
ADC Therapeutics taps Avid for production of its new blood cancer med ZynlontaWith an FDA approval in hand, ADC Therapeutics has enlistedits old friend Avid Bioservices to rev up commercial manufacturing for its new drug Zynlonta. ADCtapped Avid, which started handlingcl2021/5/21
-
AstraZeneca hits U.K. antitrust review with $39B Alexion buy after U.S. FTC clearanceAstraZeneca investors breathed a sigh of relief last month when the U.S. antitrust watchdog cleared the company’s proposed $39 billion acquisition of Alexion Pharma. Turns out, that go-ahead was no g2021/5/21
-
Lilly, Innovent's Tyvyt nabs FDA review in front-line lung cancer. Could price pressure finally reach the PD-1/L1 class?Tuesday, Innovent Biologics and partner Eli Lilly said the FDA hadacceptedtheir application for Tyvyt, or sintilimab, in combination with Lilly’s own Alimta and platinum chemotherapy for newly diagno2021/5/19
-
Novartis' Sandoz embarks on €150M antibiotics manufacturing upgrade in EuropeWhile much of the pharma industry has shifted its focusaway from antibiotics, Novartis' Sandoz unit is doing just the opposite and is chartingnext steps in amulti-year manufacturing upgrade in Europe2021/5/19